631 results on '"Cleton-Jansen, Anne-Marie"'
Search Results
2. A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target
3. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis
4. Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)
5. The Variable Genomic Landscape During Osteosarcoma Progression: Insights From a Longitudinal WGS Analysis.
6. The role of mesenchymal stem cells in bone cancer
7. Zebrafish models for studying bone tumors
8. Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing
9. A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation
10. A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival
11. IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft
12. Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers
13. Soft tissue aneurysmal bone cyst: six new cases with imaging details, molecular pathology, and review of the literature
14. Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line
15. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation
16. Supplementary Data from Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors
17. Supplementary material from Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression
18. Supplementary Data from Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents
19. Supplementary Figure 2 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
20. Supplementary Figure 1 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
21. Supplementary Figure 1 from Bone Morphogenetic Protein 7 in the Development and Treatment of Bone Metastases from Breast Cancer
22. Supplementary Methods, Figure Legends 1-3, Table Legends 1-6 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
23. Supplementary Table 1 from Bone Morphogenetic Protein 7 in the Development and Treatment of Bone Metastases from Breast Cancer
24. Supplementary Tables 1-6 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
25. Supplementary Table 2 from Bone Morphogenetic Protein 7 in the Development and Treatment of Bone Metastases from Breast Cancer
26. Data from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
27. Supplementary Methods and Materials from Bone Morphogenetic Protein 7 in the Development and Treatment of Bone Metastases from Breast Cancer
28. Supplementary Figure 3 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
29. No NFATC2 fusion in simple bone cyst of the jaw
30. Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia
31. Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype
32. Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/β-catenin signaling
33. Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes
34. SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin
35. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy
36. Expanding the Spectrum of EWSR1-NFATC2-rearranged Benign Tumors
37. Low-grade central fibroblastic osteosarcoma may be differentiated from its mimicker desmoplastic fibroma by genetic analysis
38. Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma
39. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity
40. Additional file 1 of Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)
41. Additional file 2 of Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)
42. Molecular pathology and its diagnostic use in bone tumors
43. Annexin A1 regulates TGF-β signaling and promotes metastasis formation of basal-like breast cancer cells
44. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease
45. Role of mesenchymal stem cells in bone cancer; initiation, propagation and metastasis
46. Zebrafish models for studying bone cancers: mutants, transgenic fish and embryos
47. List of Contributors
48. Sensitive and Specific KRAS Somatic Mutation Analysis on Whole-Genome Amplified DNA from Archival Tissues
49. NTRK fusions are extremely rare in bone tumours
50. Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.